Rybelsus Shortage: Current Status by Strength and What to Do

No. Rybelsus is not in shortage now. Semaglutide: the injection shortage ended on February 21, 2025. The phase-out applies to older Rybelsus tablets.

Shortage: Resolved
Prescription: RequiredFDA label (DailyMed)

Rybelsus: the basics

How long it remains in the body

Half-life is about 1 week: half disappears after 7 d, and about 3% remains after five half-lives (35 d).

Weight loss in its main trial

In PIONEER 1, people with type 2 diabetes lost 3.7 kg over 26 weeks, compared with 1.4 kg on placebo.

How the price changes over time

The maker's price page provides monthly price points in US dollars for both the list price and self-pay offers.

Sources: FDA label (DailyMed), healthsystemtracker.org, Novo Nordisk pricing, Novo Nordisk.

Every legal way to get Rybelsus, ranked

Ways to get it, ranked by lowest price
Route	Who it is for	What you pay
Your doctor, with insurance and the savings card	Commercial insurance that covers it	For 1, 2 or 3 months, fills cost as little as $25

Prices checked November 2026. Each price links to the source page.

Sources: Novo Nordisk pricing, rybelsus.com, FDA.

Who qualifies

A prescription is required for all GLP-1s sold in the US. A prescriber writes it for one of the approved uses listed on the label:

Used with diet and exercise, it lowers blood sugar in adults with type 2 diabetes.
It lowers the risk of heart attack, stroke or heart-related death in adults with type 2 diabetes who are at high risk.

Required: FDA label from DailyMed

Shortage status

Semaglutide: the injection shortage ended on February 21, 2025. The phase-out applies to older Rybelsus tablets.

Semaglutide supply, separated by product
Product	FDA status	Availability
Rybelsus tablet 3 mg, 7 mg, 14 mg	To Be Discontinued	Replaced by Ozempic (semaglutide) tablets

First added to the FDA shortage list: March 2022
Shortage resolved: February 21, 2025
On April 22, 2025, state pharmacies were required to stop compounding copies
On May 22, 2025, outsourcing facilities were required to stop

Sources: FDA, api.fda.gov.

Scam signals

No prescription needed: a seller that does not require one is not a licensed US pharmacy.
Because the FDA has not approved compounded drugs, compounded versions are not Ozempic, Wegovy, Mounjaro or Zepbound.
Salt variations: the active ingredient in approved drugs does not match semaglutide sodium or semaglutide acetate.
Misleading claims about matching the brand led the FDA to send 30 warning letters to telehealth companies.
The FDA documented 990 adverse event reports linked to compounded semaglutide.
The FTC took action against one program because its monthly prices did not include the drug; read the NextMed review.

Sources: Novo Nordisk pricing, rybelsus.com, FDA.

Find it in your state

Hims & Hers: its service does not cover all 50 states
Noom Med is not available in all 50 states
NovoCare Pharmacy: its delivery network reaches every one of the 50 states, along with DC, Puerto Rico

The route changes most because of Medicaid rules. Medicaid rules have the greatest effect on the route. Currently, 10 state Medicaid programs cover GLP-1s for weight loss. Choose your state to view its drug list and prior authorization rules:

Sources: hims.com, noom.com, NovoCare.